Charles Schwab Investment Management Inc. Boosts Position in 10x Genomics $TXG

Key Points

• Charles Schwab Investment Management Inc. increased its stake in 10x Genomics by 20.2%, holding 648,410 shares worth approximately $5.66 million as of the end of the first quarter.
• Insider transactions revealed that Benjamin J. Hindson and CFO Adam Taich both sold shares, reducing their ownership by 1.67% and 6.73% respectively.
• 10x Genomics reported a significant earnings beat, posting $0.28 EPS for the last quarter, compared to an expected loss of ($0.35), and achieved a revenue of $172.91 million.

Charles Schwab Investment Management Inc. boosted its position in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 20.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 648,410 shares of the company's stock after acquiring an additional 108,744 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.53% of 10x Genomics worth $5,661,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in 10x Genomics by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 11,118,086 shares of the company's stock valued at $97,061,000 after acquiring an additional 184,537 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in 10x Genomics by 98.0% during the 1st quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 104,512 shares of the company's stock valued at $912,000 after acquiring an additional 51,725 shares during the period. ING Groep NV boosted its holdings in 10x Genomics by 154.4% during the 1st quarter. ING Groep NV now owns 191,800 shares of the company's stock valued at $1,674,000 after acquiring an additional 116,400 shares during the period. PNC Financial Services Group Inc. boosted its holdings in 10x Genomics by 153.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company's stock valued at $45,000 after acquiring an additional 3,119 shares during the period. Finally, Blueshift Asset Management LLC purchased a new position in 10x Genomics during the 1st quarter valued at about $95,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Serge Saxonov sold 9,348 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the transaction, the chief executive officer owned 945,892 shares of the company's stock, valued at approximately $13,043,850.68. The trade was a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the transaction, the insider directly owned 440,888 shares in the company, valued at $6,079,845.52. This represents a 1.67% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 39,149 shares of company stock valued at $539,865. Company insiders own 10.03% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on TXG shares. Stephens restated an "overweight" rating and set a $14.00 target price on shares of 10x Genomics in a report on Thursday, May 15th. Morgan Stanley lowered their target price on 10x Genomics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Tuesday, August 12th. JPMorgan Chase & Co. lowered their target price on 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Weiss Ratings restated a "sell (e+)" rating on shares of 10x Genomics in a report on Saturday. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 price objective on 10x Genomics and gave the company a "hold" rating in a research note on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $13.54.

10x Genomics Price Performance

Shares of NASDAQ TXG traded down $0.64 during midday trading on Tuesday, hitting $13.37. 2,277,429 shares of the company's stock were exchanged, compared to its average volume of 2,870,462. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $24.76. The company has a market cap of $1.66 billion, a PE ratio of -19.10 and a beta of 2.00. The firm's fifty day simple moving average is $13.03 and its 200-day simple moving average is $10.71.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.63. The business had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business's quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. Equities analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.